Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07045857

Recurrence of H Pylori : Incidence and Influential Factors.

This study aims to determine recurrence rates, identify influential factors, investigate key factors that contribute to recurrence, evaluate treatment effectiveness and to assess the efficacy of different eradication regimens and their role in reducing recurrence.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Sohag University Hospital

Sohag, Egypt

Location status: Recruiting

Location contact

Magdy M Amin, Professor

CONTACT

01090801900

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age: 18-75 years old.
  • H. pylori infection: Confirmed by endoscopy, biopsy, or non-invasive tests (e.g., urea breath test, stool antigen test).
  • Symptoms: Presence of dyspepsia, peptic ulcer disease, or other H. pylori-related symptoms.
  • Laboratory tests: Normal liver and kidney function, and no significant abnormalities in blood counts.

Exclusion criteria

  • Patients receiving eradication therapy in the past taking proton pump inhibitors,, H2 blockers ,,bismuth ,, antibiotics or other medications that interfere with the result of the examination in the recent 4 weeks.
  • Gastrointestinal disorders: Severe gastrointestinal disorders (e.g., gastric cancer, inflammatory bowel disease ,gastric or duodenal ulcer with current or recent bleeding , or clinical significant gastrointestinal bleeding within 4 weeks of randomization).
  • Malignancies: Active or recent malignancies.
  • Severe comorbidities: Unstable or severe comorbidities (e.g., heart failure, liver cirrhosis).

Treatment and study plan

follow up of patients that had H. Pylori infection and recieved medical treatment for recurrence

Behavioral

follow up of patients that had H. Pylori infection and recieved medical treatment for recurrence and influential factors for recurrence

Primary outcomes

  1. recurrence of H. Pylori infection in patients who recieved medical treatment

    Time frame: 4 weeks after successful medical treatment

    H. Pylori antigen in stool

Study contacts

Contact information is provided by the study sponsor or research team.

Thomas W Thabet, Resident

CONTACT

[email protected]

01286046059

Usama M Abdelaal, Professor

CONTACT

01065962094

Sponsors and collaborators

Lead sponsor

Sohag University

Other

Registry information

Official study title

Recurrence of H Pylori : Incidence and Influential Factors in Sohag Government.

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Jul 1, 2025
Registry last updated
Jul 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.